Efmoroctocog Alfa News
Efmoroctocog Alfa currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Efmoroctocog Alfa with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Elocta can be used for all age groups.
- Evidence level: L1
- Predicted indications (20):
- pseudo-von Willebrand disease (100.0%)
- primary release disorder of platelets (100.0%)
- Glanzmann thrombasthenia (100.0%)
- hemophilia (100.0%)
- Scott syndrome (100.0%)
- acquired coagulation factor deficiency (100.0%)
- symptomatic form of hemophilia in female carriers (99.9%)
- bleeding diathesis due to a collagen receptor defect (99.9%)
- hemorrhagic disorder due to a constitutional thrombocytopenia (99.9%)
- fetal and neonatal alloimmune thrombocytopenia (99.8%)
- hemophilia A with vascular abnormality (99.8%)
- thrombotic thrombocytopenic purpura (99.7%)
- platelet-type bleeding disorder (99.7%)
- factor XI deficiency (99.6%)
- Ehlers-Danlos syndrome, fibronectinemic type (99.6%)
- flood factor deficiency (99.4%)
- methylcobalamin deficiency type cblG (99.4%)
- familial thrombomodulin anomalies (99.3%)
- hereditary thrombocytosis with transverse limb defect (99.3%)
- hemorrhagic disorder due to a platelet anomaly (99.3%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.